Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from Paradigm Biopharmaceuticals ( (AU:PAR) ).
Paradigm Biopharmaceuticals has launched ‘InvestorHub,’ a new platform designed to engage shareholders and market participants by providing easy access to company announcements and updates. This initiative coincides with a critical phase for Paradigm as it progresses its Phase 3 clinical trial for iPPS in treating knee osteoarthritis, with significant recruitment and analysis milestones expected over the next year. The platform will facilitate direct engagement with the company’s leadership, marking a transformational period for Paradigm as it advances its global study.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.73 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Ltd. is a late-stage drug development company focused on improving patients’ health by discovering, developing, and delivering pharmaceutical therapies. The company is currently concentrating on developing injectable pentosan polysulfate sodium (iPPS) for treating diseases where inflammation plays a significant role, such as osteoarthritis.
Average Trading Volume: 799,555
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$117M
See more data about PAR stock on TipRanks’ Stock Analysis page.